8 antibody drug conjugate protocols entering first line oncology in 2026 As 2026 opens, global oncology networks are witnessing a paradigm shift as antibody-drug conjugates move from salvage therapy to first-line treatment for non-small cell lung cancer. This transition is underpinned by new clinical guidelines from the American Society of Clinical Oncology that prioritize targeted payload delivery over traditional systemic chemotherapy. Major medical centers in New...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
